Suzhou Haijing Pharmaceutical Technology

Suzhou Haijing Pharmaceutical Technology is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative RNA-based therapeutics. The company leverages a proprietary GalNAc-siRNA conjugation platform to develop long-acting treatments for chronic diseases, with a primary focus on cardiovascular and metabolic health. Its lead programs include siRNA candidates targeting Factor XI for the prevention of thrombosis and ANGPTL3 for the treatment of hypertriglyceridemia. By utilizing advanced delivery technologies, Suzhou Haijing aims to provide patients with highly specific, potent, and infrequently administered therapies for high-prevalence conditions.